Navigation Links
Amicus Therapeutics Announces Change to Board of Directors
Date:2/18/2009

CRANBURY, N.J., Feb. 18 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) announced today that Stephen Bloch, M.D., General Partner with Canaan Equity Partners, has resigned from the Company's Board of Directors effective February 17, 2009. Dr. Bloch served as a member of Amicus' board since 2004.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

FOLD-G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
2. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
3. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
4. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
5. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
6. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
7. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
8. Amicus Therapeutics Opens Research Facility in San Diego
9. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
10. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
11. Amicus Therapeutics Announces First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... A luxury car manufacturer ... popular corporate team building events this summer. , Each team gathered ... competition to whet their palettes. Three teams were then formed, and each ...
(Date:7/27/2017)... RESEARCH TRIANGLE PARK, N.C., July 27, 2017 ... today announced its financial results for the second ... "Our second quarter total net revenues ... level ever," said Martine Rothblatt, Ph.D., United Therapeutics ... believe that Orenitram is well-positioned given the large ...
(Date:7/26/2017)... ... 2017 , ... CardioWise, Inc. , is pleased to ... analysis software, and an associated pending patent from Johns Hopkins Technology Ventures through ... uses high resolution cardiac CT to analyze cardiac wall motion that provides extraordinary ...
(Date:7/26/2017)... ... July 26, 2017 , ... Franz ... Semantic Graph Database technology for Knowledge Graphs, today announced Gruff v7.0 , ... Gruff provides novice users and graph experts the ability to visually build queries ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):